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Abstract
Background—A new serogroup A meningococcal conjugate vaccine (PsA-TT, MenAfriVac™) 
has been developed to combat devastating serogroup A Neisseria meningitis (MenA) epidemics in 
Africa. A mass immunization campaign targeting 1–29 year olds was conducted in Burkina Faso 
in December 2010. Protection of subsequent infant cohorts will be necessary through either 
introduction of PsA-TT into the routine Expanded Programme on Immunization (EPI) or periodic 
repeat mass vaccination campaigns.
Objectives—To inform future immunization policy for PsA-TT vaccination of infants through a 
comparison of PsA-TT campaign vaccination coverage and routine measles-containing vaccine 
(MCV) coverage in Burkina Faso.
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Methods—A national survey was conducted in Burkina Faso during December 17–27, 2011 
using stratified cluster sampling to assess PsA-TT vaccine coverage achieved by the 2010 
nationwide immunization campaign among 2–30 year olds and routine MCV coverage among 12–
23 month olds. Coverage estimates and 95% Confidence Intervals (CI) were calculated, reasons 
for non-vaccination and methods of campaign communication were described, and a multivariable 
analysis for factors associated with vaccination was conducted.
Results—National overall PsA-TT campaign coverage was 95.9% (95% CI: 95.0–96.7) with 
coverage greater than 90% all 13 regions of Burkina Faso. National overall routine MCV coverage 
was 92.5% (95% CI: 90.5–94.1), but ranged from 75.3% to 95.3% by region. The primary 
predictor for PsA-TT vaccination among all age groups was a head of household informed of the 
campaign. PsA-TT vaccination was more likely in residents of rural settings, whereas MCV 
vaccination was more likely in residents of urban settings.
Conclusion—Overall national vaccination rates in Burkina Faso were similar for PsA-TT and 
MCV vaccine. The regions with MCV coverage below targets may be at risk for sub-optimal 
vaccination coverage if PsA-TT is introduced in EPI. These results highlight the need for 
assessments of routine vaccination coverage to guide PsA-TT immunization policy in meningitis 
belt countries.
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Serogroup A meningococcal meningitis; Conjugate meningococcal vaccine; PsA-TT; Measles; 
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1. Background
In December 2010, Burkina Faso became the first country to introduce PsA-TT 
(MenAfriVac™), a novel meningococcal serogroup A polysaccharide conjugate vaccine. 
PsA-TT was developed to eliminate epidemic meningitis as a public health problem in the 
‘meningitis belt’ of Sub-Saharan Africa, a region stretching from Senegal to Ethiopia and 
home to 430 million people. The country vaccinated over 11 million persons, or 
approximately 70% of the country’s population, via a 10-day nationwide mass immunization 
campaign, achieving vaccination coverage of 95.9% in the target group of 1–29 year-olds 
[1].
The strategy for PsA-TT vaccine introduction in 26 African countries from 2010 to 2016 
consists of two phases [2]. In the first phase, one-time mass immunization campaigns 
targeting 1–29 year olds are conducted to rapidly interrupt disease transmission and 
eliminate carriage. In the second phase, new birth cohorts will be protected through either 
introduction of the vaccine into the Expanded Programme on Immunization (EPI) schedule 
as a 1 or 2 dose series with likely measles-containing vaccine (MCV) coadministration, 
and/or via periodic repeat mass vaccination campaigns targeting children aged 1–4 years [3]. 
Pending the results of infant clinical trials [4], the vaccine has not yet been licensed for use 
in infants and no countries have introduced the vaccine through routine EPI. The future 
vaccination strategy for the protection of infants will depend in part on routine EPI coverage 
in implementing countries [2].
Meyer et al. Page 2
Vaccine. Author manuscript; available in PMC 2018 January 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
To guide future PsA-TT vaccine policy in infants, we assessed routine MCV coverage 
among 12–23 month old residents of households included in a nationwide survey of PsA-TT 
vaccine coverage following the mass immunization campaign in Burkina Faso [1], compared 
PsA-TT campaign coverage with routine MCV coverage estimates within households and 
among regions, and identified predictors for vaccination and reasons for non-vaccination 
with PsA-TT and MCV vaccines.
2. Methods
Burkina Faso is a hyperendemic country for meningococcal meningitis in West Africa with a 
2010 population of 15.7 million persons [5]. The nationwide PsA-TT immunization 
campaign targeting 1–29 year olds, or approximately 11 million persons, was conducted 
from December 6 to 15, 2010. A vaccination card designed specifically for the campaign 
was distributed to each vaccinated person. At the time of the survey in Burkina Faso, MCV 
was delivered through routine EPI as a single dose between the ages of 9 and 11 months and 
through periodic supplemental immunization activities (SIAs). Receipt of measles 
vaccination delivered through EPI is documented by a vaccination book used to record 
routine immunizations.
A national survey was conducted in Burkina Faso during December 17–27, 2011, using 
stratified cluster sampling to assess PsA-TT vaccine coverage achieved by the nationwide 
immunization campaign among 2–30 year olds (those aged 1–29 years during the December 
2010 campaign) and routine MCV coverage among 12–23 month olds. The sampling frame 
was derived from 2011 population estimates projected from the 2006 national census [6]. 
Strata were defined by the 13 administrative regions. Twenty-five enumeration areas were 
selected from each stratum in the first stage using probability proportional to size. In each 
enumeration area, field teams demarcated the boundaries of the enumeration area, 
enumerated all the households, and systematically selected 20 households by calculation of a 
sampling interval. All persons aged 1–30 years residing in selected households were 
included. Based on demographic indictors of household size and age distribution in Burkina 
Faso, a sample size of 500 households per stratum was calculated to provide regional 
estimates for PsA-TT vaccination for three age groups (2–5 years, 6–15 years, and 16–30 
years) and national MCV coverage estimate in 12–23 month olds with ±8% precision, 
assuming 80% coverage, a 95% probability of achieving the desired precision, a design 
effect of two, and a 5% nonresponse rate.
A questionnaire was administered to heads of household to collect household demographic 
and socioeconomic information. For PsA-TT campaign-eligible subjects, vaccination status, 
modes of communication regarding the PsA-TT campaign, and reasons for non-vaccination 
were recorded by interviewing eligible household members, or the head of household or 
other parent for children too young to respond. Vaccination status was determined by review 
of a PsA-TT campaign vaccination card or by recall. Persons with documentation of receipt 
of PsA-TT by vaccination card or who stated that they had received the vaccine without 
documentation by vaccination card were defined as vaccinated. Additionally, presence in 
Burkina Faso during the PsA-TT campaign was recorded to obtain campaign coverage 
estimates and 2011 population coverage estimates, accounting for migration.
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For MCV-eligible subjects aged 12–23 months, vaccination status, date of vaccination, and 
reasons for non-vaccination were recorded by interview with parent or guardian of the child. 
Vaccination status was determined by review of the child’s vaccination book or by parental 
recall. Children with documentation of MCV receipt by vaccination book or a parent that 
stated the child had received the vaccine without documentation by vaccination book were 
defined as vaccinated. Of note, a nationwide measles SIA targeting children 9–59 months of 
age was conducted in April 2011 following WHO recommendations for measles elimination 
by providing high vaccination coverage with two doses of MCV [7]. Thus, survey 
participants aged 17–23 months were eligible for vaccination through both routine EPI and 
the SIA. Receipt of vaccination through this SIA was not documented in the routine EPI 
vaccination book. For children with report of MCV receipt but without documentation in the 
routine immunization book, interviewers were instructed to elicit information surrounding 
the administration of the vaccine and confirm that it was received through routine health 
services and not during this SIA.
Before survey implementation, a pilot study and formal training of the 65 field teams were 
conducted. Each field team consisted of two interviewers and a supervisor who were under 
the direction of a regional supervisor, for a total of 208 investigators deployed to the field for 
the survey.
Estimates of coverage and (Wilson) 95% confidence intervals (CIs) accounted for the 
stratified cluster design using SAS 9.3 (SAS Institute). For the national coverage estimates, 
stratum-specific weights were included. Multivariable analysis for factors associated with 
vaccination was conducted using SAS-callable SUDAAN v10 to obtain adjusted relative 
risks (aRR) and 95% CIs. For this analysis, the factors of interest were household-level; 
therefore, to avoid the correlation among household members, one randomly selected person 
per age group per household was included for the PsA-TT analysis and one child per 
household for the MCV analysis. All variables determined a priori as potential factors 
associated with vaccination were included in the model, regardless of univariate 
significance. The design effects (DE) were estimated on the sample with one person per HH 
using survey procedures accounting for the cluster sampling only. The intraclass correlations 
(ICC) were estimated by (DE − 1)/(mean number observations per cluster − 1).
This evaluation was approved by the human subjects advisor at CDC as public health 
practice and exempted from full review by the CDC Institutional Review Board and the 
Burkina Faso Ministry of Health ethics committee. Informed consent for participation was 
obtained prior to enrollment.
3. Results
A total of 6455 households were surveyed from 325 enumeration areas. The sampled 
enumeration areas were geographically diverse, covering 57 of 63 health districts, and all 13 
regions. Among these households, 6434 (99.7%) consented to survey participation and 
25,627 persons were enrolled: 23,957 PsA-TT-eligible persons from 6102 households and 
1670 MCV-eligible children from 1340 households. The majority (97.5%) of households 
with a 12–23 month old also had at least one member eligible for PsA-TT vaccination 
Meyer et al. Page 4
Vaccine. Author manuscript; available in PMC 2018 January 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
during the campaign. Among enrolled persons, 219 (0.9%) were excluded from the analysis 
due to unknown or ineligible age: 67 (0.3%) PsA-TT-eligible persons and 152 (9.1%) MCV-
eligible children.
Among the 23,769 persons aged 2–30 years surveyed, 23,577 (99.2%) reported presence in 
Burkina Faso during the 2010 vaccination campaign. Vaccination coverage among persons 
residing in Burkina Faso during the campaign vs. coverage among all surveyed persons, 
regarding of presence during the campaign, did not differ substantially: 95.9% (95% CI: 
95.0–96.7) vs. 95.1% (95% CI: 94.2–95.9), respectively, and thus only those results among 
persons present in Burkina Faso during the campaign are reported.
National campaign PsA-TT vaccine coverage was 95.9%: 74.3% by vaccine card and 21.6% 
by recall (Table 1). Vaccination coverage was high in all 13 regions (Table 1a), in all age 
groups (Table 2), and did not differ significantly among females and males (96.1% vs. 
95.8%, p = 0.49). Coverage was higher in rural settings compared to urban settings (96.7% 
vs. 92.7%, p = <0.01).
National routine MCV coverage among 12–23 month olds was 92.5%, with 53.6% by 
vaccination book and 38.9% by recall only. Overall coverage by region ranged from 75.3% 
to 96.3%, with coverage by vaccination book ranging widely from 17.3% to 76.3% (Tables 1 
and 2). There was no difference in vaccination status among females and males (92.4% vs. 
92.5%, p = 0.97). Reported routine EPI coverage among 17–23 month olds (n = 681) who 
were eligible for both routine EPI and SIA-administered MCV during the study period was 
93.3%, similar to the coverage among the 12–16 month olds who were only MCV-eligible 
through routine EPI (p = 0.51). In addition, the proportion of 17–23 month olds with report 
of MCV vaccination by recall only was 35.4% compared to 42.2% among 12–16 month olds 
(p = 0.05). MCV vaccination was higher among infants in urban vs. rural settings (97.9% vs. 
91.8%, p = 0.04). Among the 593 children with known date of birth and known date of 
MCV vaccination, the median age of vaccination was 9 months (range 6–22 months).
Among the 5025 households participating in the PsA-TT survey with more than 1 enrolled 
person in the household and where vaccination status of household members was known, 
high concordance of vaccination status within the household was observed: all members of 
the household received PsA-TT in 4565 (90.9%) of households, and in 121 (2.4%) 
households, no persons received PsA-TT. Among the 119 households participating in the 
MCV survey with more than 1 enrolled child in the household and where the vaccination 
status was known, high concordance was observed for MCV vaccination: all children in the 
household received MCV in 111 (93.3%) of household and in 5 households (4.2%) none of 
the children received MCV vaccine.
Among the 1242 households that had at least one PsA-TT and MCV eligible participant and 
known vaccination status of all household members, 1059 (85.2%) households were fully 
vaccinated for both PsA-TT and MCV. In 104 households (8.4%), at least one eligible 
household member received PsA-TT vaccine but no eligible household members received 
MCV vaccine. In contrast, only 10 households (0.01%) had at least one child vaccinated for 
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MCV but no household members vaccinated for PsA-TT. In only six households (<0.01%), 
no eligible household members received PsA-TT or MCV vaccine.
Among the 775 persons unvaccinated during the PsA-TT campaign and the 115 children 
unvaccinated for routine MCV with a known reason for non-vaccination, the most 
commonly cited reasons for both vaccines were ‘not informed’ and ‘absence’ (Table 3). The 
most commonly reported modes of PsA-TT campaign communication were criers (social 
mobilizers) (36.8%), and community health workers (24.0%) (Fig. 1).
The primary predictor for PsA-TT vaccination in all age groups was having a head of 
household informed of the PsA-TT campaign: aRR of 1.35 in 2–5 year olds (95% CI 1.17–
1.56), aRR of 1.35 in 6–15 year olds (95% 1.18–1.56), and aRR of 1.47 in 16–30 year olds 
(95% 1.28–1.70). Factors significantly associated with receipt of campaign communication 
were head of household employed as a salaried worker (aRR 1.04, 95% CI 1.01–1.07) and 
rural setting (aRR 1.04, 95% CI 1.01–1.03). There was no association between vaccination 
and sex, employment status of head of household, and household size (Table 4).
Receipt of MCV was less likely in rural settings (aRR 0.94, 95% CI 0.90–0.97), and less 
likely with a head of household with any employment (aRR 0.94, 95% CI 0.91–0.98), 
defined as any wage or goods-receiving employment, including agriculture (Table 4). 
Vaccination was not associated with sex, education status of head of household, presence of 
other age groups in the house outside of infant age group, or household size.
4. Discussion
The results of this survey demonstrate that Burkina Faso successfully achieved the first 
phase of PsA-TT vaccine introduction through high mass vaccination campaign coverage in 
the target group aged 1–29 years. However, with the accumulation of susceptible birth 
cohorts since the 2010 campaign, implementation of a strategy for protection of infants is 
critical. As introduction of PsA-TT into EPI through co-administration with MCV at age 9 
months is likely, routine MCV vaccination coverage estimates may be an indicator for future 
PsA-TT coverage. Our concurrent evaluation of routine MCV coverage among 12–23 month 
olds enrolled from the same households as PsA-TT eligible persons demonstrated that 
overall estimated routine MCV coverage was high, although certain regions of Burkina Faso 
may be at risk for sub-optimal PsA-TT vaccination if introduced into EPI.
While we found similar overall rates of PsA-TT campaign (95.9%) and routine MCV 
(92.5%) vaccination coverage, vaccination by card or vaccine book differed substantially: 
74.3% for PsA-TT and 53.6% for MCV, with an even greater disparity by region. The high 
percentage of recall-only MCV vaccination substantially limits the interpretation of routine 
MCV coverage as a proxy for future PsA-TT vaccine coverage if delivered through routine 
EPI. It is likely that some of the 17–23 month old children who reported MCV receipt 
without documentation in the vaccine book received MCV through the SIA, and not through 
routine services as reported. However, the 2010 Burkina Faso Demographic Health Survey–
Multiple Indicator Cluster Survey 4 (DHS–MICS4) found a slightly lower overall MCV 
coverage of 87.3%, but much higher coverage documented by card at 75.8%, and only 
Meyer et al. Page 6
Vaccine. Author manuscript; available in PMC 2018 January 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
11.5% by recall. The reasons for this substantial disparity among the two surveys, which 
both enrolled large sample sizes and utilized similar sampling strategies, are unclear. Despite 
this uncertainty, the regions with the lowest MCV vaccination documented by card in our 
survey corresponded to those with the lowest overall coverage in the DHS–MICS4 survey 
[8]. Regardless, the overall MCV coverage estimates for Sahel and Sud-Ouest region were 
below international measles elimination targets for coverage of the first routine MCV dose 
[7]. Thus, these regions in Burkina Faso may benefit from either repeat PsA-TT mass 
immunization campaigns alone or as a supplement to routine immunization services similar 
to the “Catch-Up, Keep-Up, Follow-up” measles elimination strategy [9,10], as opposed to 
introduction of PsA-TT into routine EPI alone for protection of infant cohorts. Sahel and 
Sud-Ouest, despite low overall MCV vaccination of 75.3% and 82.6% (17.3% and 35.7% by 
vaccine book), respectively, both attained very high PsA-TT campaign coverage of 94.5% 
and 95.9% (76.3% and 76.8% by vaccination card). Furthermore, achievement of high PsA-
TT coverage in Sahel and Est, regions with low population density and large nomadic 
populations, demonstrates that the communication and operational strategies employed to 
reach these populations during the PsA-TT campaign were successful. As opposed to the 
higher routine MCV coverage in urban settings, campaign PsA-TT coverage was higher in 
rural settings, which comprise nearly 80% of the country [11], suggesting that future 
national PsA-TT coverage rates may be higher with a campaign approach as long as vaccine 
demand remains high and campaigns remain well-managed.
The decision to introduce PsA-TT into EPI or via follow-up immunization campaigns will 
involve other factors in addition to routine vaccine coverage estimates, including safety and 
immunogenicity of coadministration with other vaccines, duration of protection, and cost. 
Results from a clinical trial demonstrate that concomitant administration of PsA-TT with 
local EPI vaccines is safe and immunogenic [12]; an evaluation to determine the optimal 
schedule and formulation of PsA-TT for routine vaccination in co-administration with 
measles vaccine is ongoing [4]. A mathematical model developed to identify optimal long-
term PsA-TT vaccination strategies using surveillance and carriage data from Burkina Faso 
demonstrated that either strategy, introduction into EPI or repeat mass campaigns, would be 
effective in substantially reducing MenA incidence over a 40 year period following the 
initial mass immunization campaign. The most effective modelled strategy is mass 
immunization campaigns in 1–5 year olds every 5 years, with introduction of PsA-TT into 
the routine EPI program resulting in higher predicted MenA incidence than periodic 
immunization campaigns [13]. However, there is limited data on the duration of protection 
following PsA-TT vaccination, and thus forecasts of vaccine program impact may vary 
depending on assumptions made about duration of protection. A cost savings analysis 
conducted using data from neighboring Niger found that all evaluated vaccination strategies, 
including a single dose of PsA-TT at 9 months or at 12–18 months, a two-dose series at 14 
weeks and 9 months, or follow-up campaigns in 1–4 year olds, are projected to result in 
considerable savings to the health systems of affected countries. However, introduction of 
PsA-TT into EPI as a single dose at age 9 months was expected to have the greatest cost 
savings [14]. Given the higher predicted disease reductions through a periodic campaign 
approach yet lower projected costs through introduction into EPI, a long-term and 
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sustainable plan to eliminate MenA meningitis epidemics will need to carefully weigh the 
cost versus effectiveness of the different strategies under consideration.
Whether the recommended strategy for protection of infant cohorts involves repeat mass 
campaigns, introduction of PsA-TT into EPI, or both, achieving and sustaining high PsA-TT 
coverage in ‘meningitis belt’ countries could prove challenging. Meningitis belt countries 
are among the least developed in the world, constituting 9 of the 10 lowest-ranking countries 
on the United Nations Human Development Index [15]. Weak and fragile public health 
infrastructures may limit the delivery of routine immunization services in meningitis belt 
countries, which represent 5 of the 10 countries in the world with the lowest routine MCV 
coverage [16]. Even with Burkina Faso’s high-performing immunization program, which 
achieved a remarkable increase in reported routine MCV coverage from 48% in 2000 to 92% 
in 2010 and multiple years with SIA coverage >95% [17], the country experienced its largest 
ever recorded measles epidemic in 2009 with over 54,000 cases. Non-vaccination, likely 
longstanding as evidenced by the high disease rates in adolescents and adults, was identified 
as the greatest risk factor [18]. These challenges highlight the need for support for 
immunization programs with careful monitoring of vaccine introduction and strong 
surveillance systems to ensure sustained high coverage and rapid identification of gaps in 
population immunity.
The first phase of PsA-TT vaccine introduction in Burkina Faso and elsewhere in the 
meningitis belt has been a remarkable public health success. By the end of 2013, over 150 
million persons in 12 countries received PsA-TT vaccine via mass immunization campaigns, 
with national and subnational administrative vaccine coverage estimates at >90% in most 
countries. Substantial impact of the vaccine has already been observed on MenA incidence 
and carriage in countries that have introduced the vaccine [19–21], and overall, the number 
of suspected meningitis cases in the Meningitis Belt reached a 10-year low in 2013 [22]. 
With over 160 million more persons in 14 countries targeted to receive the vaccine by the 
end of 2016 through mass campaigns, PsA-TT holds great promise for further reductions in 
MenA disease. To sustain these gains over the long term, protection of infant cohorts is a 
critical next step. As vaccine policy around this next phase evolves, an assessment of each 
country’s routine vaccination coverage and immunization program will be important to 
guide decision-making.
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Fig. 1. 
Mode of PsA-TT campaign communication by age group.
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